OASIS SOLID-PHASE EXTRACTION PRODUCTS

[ OASIS SOLID-PHASE EXTRACTION PRODUCTS ]

Simplifying

Solid-Phase Extraction

2

* U.S. patents 5,882,521 (1996), 5,976,376 (1998), 6,106,721 (1999), 6,254,780 (2001), 6,322,695 (2001),  
 6,468,422 (2002), 6,726,842 (2004), 6,773,583 (2004), 6,723,236 (2004)

Through the combination of innovative sorbent technology and hardware design,  
Oasis® Products have become the first choice in solid-phase extraction (SPE).  
Oasis Products are trusted by separation scientists across the globe to meet a wide 
variety of sample preparation needs, ranging from a simple and fast matrix cleanup to 
the need to solve the most difficult and highly selective sample preparation challenges. 
Researchers rely on the superior technical performance of Oasis Products to achieve 
unmatched purity, consistency, and quality in their sample preparation methods.

3

[ OASIS SOLID-PHASE EXTRACTION PRODUCTS ]

¡ 

Fastest and simplest methods leading to the cleanest samples 

¡ 

Highest sensitivity for small molecules and therapeutic peptides

¡ 

Reduced matrix effects for LC-MS/MS analyses

¡ 

Unsurpassed selectivity

¡ 

Highest SPE recovery

¡ 

Exceptional product quality and reproducibility

¡ 

Wide selection of sorbents

¡ 

Broad array of formats

4

Oasis HLB

Simplifying Solid-Phase Extraction
Waters introduced Oasis HLB in 1996, effectively changing 
the way scientists performed solid-phase extraction (SPE), as 
well as their expectations of this process. Constructed with a 
water-wettable copolymer that is stable from pH 0–14, Oasis 
HLB created a whole new range of solid-phase extraction 
method development possibilities. It is the gold standard in 
reversed-phase SPE, trusted by scientists across the world.

Traditional 5-step SPE protocol vs. the new 3-step SPE protocol with an Oasis HLB µElution Plate. (Typical loading range between  

10–375 µL undiluted plasma.)

Hydrophilic-Lipophilic Balanced Copolymer

Hydrophilic monomer

Retention of polars

Lipophilic monomer

Reversed-phase retention

Traditionally, solid-phase extraction methods have required condition and equilibration steps to prepare the sorbent for 
sample introduction. The condition step was required to wet the sorbent and allow liquid to enter the pores, enabling 
retention within the sorbent. Once wetted, the sorbent needed to be equilibrated with aqueous solution to prepare it 
for aqueous sample loading. Since Oasis HLB is a water-wettable sorbent, the analytes can interact with the sorbent 
and are retained when loaded directly onto the sorbent in an aqueous sample solution. This eliminates the condition 
and equilibration steps from the traditional solid-phase extraction protocol and reduces the number of processing 
steps from 5 to 3. The result is an average reduction in solvent consumption of up to 70% and a 40% savings in sample 
preparation time.

Save Time and Solvent by Moving from a 5-Step Protocol to a 3-Step Protocol

200 µL methanol (MeOH)

200 µL H2O

200 µL spiked dilute plasma 

(100 µL plasma + 100 µL 4% H3PO4)

200 µL 5% MeOH in H2O

25 µL * 2 MeOH

200 µL spiked dilute plasma 

(100 µL plasma + 100 µL 4% H3PO4)

200 µL 5% MeOH in H2O

25 µL * 2 MeOH

Elute

Standard (5-Step)

Simplified (3-Step)

Wash

Load

Equilibrate

Condition

5

[ OASIS SOLID-PHASE EXTRACTION PRODUCTS ]

The ability to simplify and shorten SPE protocols is due to the unique water-wettable, balanced nature of the 
hydrophilic/lipophilic Oasis Sorbent. Silica-based sorbents and other “Oasis-like” polymeric sorbents that are  
not as water-wettable as Oasis HLB sacrifice performance when eliminating these condition and equilibration  
steps. The chart below illustrates the difference that a thoroughly water-wettable sorbent such as Oasis HLB  
can make in the implementation of this simplified, 3-step protocol. Oasis HLB is able to effectively retain a wide  
range of compounds without the condition and equilibration steps. The competitors’ polymeric sorbent and a silica 
based sorbent do not work in the absence of these steps.

Simplify Solid-Phase Extraction Without Sacrificing Recovery

The percent recoveries for a diverse set of compounds remain high with Oasis HLB when the condition and equilibration steps are 

eliminated from the solid-phase extraction protocol. Under these same conditions, the silica based sorbent produces recoveries of 

less than 10 percent for all analytes. The polymeric based sorbent produces recoveries of less than 10% for 7 compounds and less 

than 20% and 50% for the other two compounds.

Additional information can be found within these application notes:

Application note

Literature code

A Simplified, Mixed-Mode Sample Preparation Strategy for Urinary Forensic Toxicology 

Screening by UPLC-MS/MS

720005290EN

A Simplified, Solid-Phase Extraction (SPE) Protocol for Bioanalysis Using Oasis HLB

720005140EN

Search by literature code at waters.com

HLB μElution plate

Polymer-based μ plate

tC18 μElution plate

100

90
80
70
60
50
40
30
20
10

0

Azidothymidine (AZT)

Propranolo

l

7-Hydroxycoumarin

Phenacetin Protriptylin

e

Amitriptylin

e

Betamethasone

Alprazola

m

Naproxe

n

6

Oasis PRiME HLB
Oasis PRiME HLB is the first-of-its-kind SPE sorbent that sets the new performance standard for routine analyses. 
The unique, patent-pending Oasis PRiME HLB Sorbent provides cleaner samples in less time and with less effort. 
These powerful and easy-to-use benefits are important since solid-phase extraction provides many benefits 
when performed prior to chromatographic analyses, especially when using mass detection.  
These benefits include a reduction in matrix effects and chromatographic complexity as  
well as the ability to increase sample concentration. However, scientists also desire 
sample preparation methods that are SIMPLE to follow while providing 
CLEANER sample eluates in the FASTEST time possible. Based on Oasis 
HLB Technology, Oasis PRiME HLB was developed to meet these 
needs with a focus on these advantages:

¡ 

Simpler

¡ 

Faster

¡ 

Even Cleaner

7

[ OASIS SOLID-PHASE EXTRACTION PRODUCTS ]

Simpler

Easy, efficient protocols 
Oasis PRiME HLB was created to have the same powerful benefits made 
possible with Oasis HLB. The Oasis PRiME HLB Copolymer is extremely 
water-wettable, making it possible to eliminate the condition and equilibration 
steps that are required when using silica-based or other polymeric sorbents. 
Without these additional steps, sorbents that are not as water-wettable are 
unable to effectively retain analytes of interest during the sample load step, 
causing a loss of recovery. The ability to skip these steps saves valuable 
sample processing time and costly solvent purchase and disposal.

Oasis PRiME HLB allows you to choose the sample preparation method 
that meets your analytical needs. The simplicity of the sorbent design and 
protocols makes it easy to implement into your laboratory's workflow without 
requiring solid-phase extraction expertise.

Load pre-treated sample

Wash: 5% MeOH

Elute: 90/10 acetonitrile/MeOH

Load pre-treated sample

Analytes pass-through unretained

Rinse to collect hold up volume  

(optional)

Use the 2-step solid-phase 
extraction protocol to remove 
matrix interferences quickly if 
your sample solution contains 
a high concentration of organic 
solvent(s) and concentration and/
or salt removal is not required. 
This protocol is perfectly suited 
for multiple residue screening of 
veterinary drugs, pesticides and 
mycotoxins in various food samples.

Use the 3-step solid-phase 
extraction protocol to remove the 
most matrix interferences, including 
salts, phospholipids, and proteins. 
This technique also allows for 
sample concentration/enrichment. 
It is the perfect solution for routine 
bioanalytical sample clean up or any 
other reversed-phase solid-phase 
extraction application.

3-step protocol (catch and release SPE)

2-step protocol (pass-through SPE)

8

Faster

Faster, more even flows across cartridges and plates with less plugging
Oasis PRiME HLB has been designed to increase speed both within the SPE device itself and in your laboratory’s 
sample processing workflow. Not only can you eliminate the condition and equilibration steps, viscous samples flow 
more easily through the cartridges and 96-well plates due to a new, optimized frit and sorbent design. Flow rates 
through the devices are much faster for common matrices such as plasma, urine, and milk. The optimal load, wash,  
and elution flow rates are achieved using less vacuum or positive pressure than with other SPE devices.

Increased Sample Processing Speed with Oasis PRiME HLB

Matrix

Device Format

Oasis PRiME HLB Speed 

Increase

1:1 Diluted Plasma

µElution Plate

2–3x Faster

1:1 Diluted Plasma

1 cc/30 mg Cartridge

4x Faster

1:1 Diluted Urine

30 mg Plate

6x Faster

1:1 Diluted Urine

10 mg Plate

2x Faster

1:1 Diluted Milk

3 cc/60 mg Cartridge

1–2x Faster

1:1 Diluted Milk

6 cc/200 mg Cartridge

2–3x Faster

Flow comparison vs. another reversed-phase SPE sorbent. Loading performed with 4 inch Hg (n=4).

Faster processing time compared to other sample preparation techniques
With the elimination of the condition and equilibration steps, Oasis PRiME HLB provides faster processing time 
compared to other sample preparation techniques such as solid-supported liquid extraction (SSLE). Scientists can 
achieve highly reproducible sample clean up with less process complexity and fewer steps.

Reduce Sample Preparation Time and Steps with Oasis PRiME HLB Compared to SSLE

Oasis PRiME HLB reduces sample preparation 

time and complexity by providing efficient sample 

preparation. Compared to SSLE, samples can be 

processed in fewer steps and less time.

SSLE
1. 

Add sample (3 min)

2. 

Wait (5–10 min)

3. 

Add extraction solvent (2 min)

4. 

Wait (5–10 min)

5. 

Extract (1 min)

6. 

Evaporate (5 min)

7. 

Reconstitute (2 min)

TOTAL 

PROCESS-

ING TIME:

28–33min.

Oasis PRiME HLB
1. 

Load pre-treated sample (4 min)

2. 

Wash: 5% MeOH (3.5 min)

3. 

Elute: 90/10 acetonitrile/MeOH (2 min)

TOTAL 

PROCESS-

ING TIME:

9.5min.

9

[ OASIS SOLID-PHASE EXTRACTION PRODUCTS ]

Even Cleaner
Oasis PRiME HLB removes more than 95% of common matrix interferences such as proteins, salts, and phospholipids, 
using the generic protocol without any additional optimization. Cleaner samples means less variability in your 
analytical results from sample to sample, increasing the robustness of your analyses. 

Food analysis can provide an exceptional challenge in sample preparation. Meat and milk samples are typically extracted 
with an acetonitrile based solvent for LC-MS determination of veterinary drug residues. Among the most significant 
co-extractable substances are fats and polar lipids, particularly phospholipids. For example, 1 mL of whole milk contains 
about 35 mg of fat and about 0.3 mg of phospholipids. A gram of pork muscle typically contains about 100 mg of fat and 
about 5 mg of phospholipids. Reversed-phase sorbents such as C18 are effective for removal of fat from the acetonitrile 
based extraction solvent, but are ineffective for removal of phospholipids. Excessive amounts of phospholipids can 
shorten LC column life and contribute to ion-suppression and contamination in the mass spectrometer. Oasis PRiME 
HLB is highly effective for removal of both phospholipids and fats from meat and milk extracts. 

Fewer phospholipids remain in the final sample eluate with the Oasis PRiME HLB Sorbent and 3-step protocol, compared to the final 

eluates using traditional 5-step protocol on the competitors' sorbents. This removal is also more reproducible with Oasis PRiME HLB 

as indicated by the error bars (n=5).

Phospholipids Remaining in Final Eluate 

Oasis PRiME HLB

Competitor SX 

Competitor SO 

PPT 1:3 

Plasma:ACN

0

7000000

6000000

5000000

4000000

3000000

2000000

1000000

Phospholipids Remaining in Final Eluate

%

0

1: MRM of 12 Channels ES+

TIC (Phospholipid)

1.87e8

4.58

4.33

Silica C18

100

1

2

3

4

5

6 min

1

2

3

4

5

6 min

%

0

1: MRM of 12 Channels ES+

TIC (Phospholipid)

1.87e8

4.33

Oasis PRiME HLB

100

Phospholipids Remaining After Pass-through Sample Clean Up

Lipid removal from acetonitrile-based meat extract results: Oasis PRiME HLB removes more than 90% of hexane-extractable total 

lipids (determined gravimetrically). Oasis PRiME HLB successfully removes both phospholipids and fats in pass-through method. 

The silica C18 sorbent removes only fats, NOT phospholipids. Removal of both of these components results in fewer matrix effects 

and less column and/or instrument contamination.

10

Reduced Matrix Effects
The presence of matrix interferences in a sample  
limits the maximum sensitivity that can be achieved.  
In addition, the removal of matrix interferences 
increases the robustness and reproducibility of  
your analytical results.

Analyte

% RSD of Matrix Factors

Amitriptyline

6.03

Nortriptyline

5.53

Imipramine

8.36

Desipramin

e

7.15

Doxepin

5.96

Following extraction with an Oasis Mixed-Mode Sorbent, the 

matrix effects were evaluated for a panel of 5 antidepressant 

drugs in multiple lots of urine. The RSD of the matrix factors was 

determined to be between 5.5 and 8.4%, which is well within 

the 15% limit required by regulatory agencies.

Sorbents
The Mixed-Mode Ion Exchange/Reversed-Phase Sorbents are all based on the Oasis HLB Copolymer to provide a 
range of options for method development.

Oasis WCX 

Mixed-Mode Weak Cation eXchange sorbent for 

strong bases and quaternary amines

Oasis MCX 

Mixed-Mode Cation eXchange sorbent for bases

Oasis MAX 

Mixed-Mode Anion eXchange sorbent for acids

Oasis WAX 

Mixed-Mode Weak Anion eXchange  

sorbent for strong acids

Oasis HLB

Hydrophilic-Lipophilic Balanced reversed-phase  

sorbent for acids, bases, and neutrals

pKa <1

pKa~5

pKa >18

pKa ~6 and ~9

Hydrophilic  

Retention  

of Polars

Lipophilic  

RP Retention

Stable from pH 0–14 

Water-wettable 

No silanol interactions

11

[ OASIS SOLID-PHASE EXTRACTION PRODUCTS ]

Sensitivity
The Oasis Mixed-Mode Sorbents, which are all 
built upon the unique water-wettable Oasis HLB 
Copolymer, provide both reversed-phase and ion 
exchange modes of retention, enabling greater 
cleanup selectivity and sensitivity for both acidic 
and/or basic compounds. An example of this 
outstanding capability can be seen with the Oasis 
µElution Plate. This product employs a patented 
design to concentrate a sample up to 15x without 
requiring evaporation or reconstitution.

LOQ of Alprazolam from Plasma

A. Matrix blank

%

0

100

1.54

1.58

1.62

1.66

1.70

1.74

1.78 min

B. 1 pg/mL 

spiked sample

%

0

100

1.54

1.58

1.62

1.66

1.70

1.74

1.78 min

1.61

1.52

1.55

1.66

1.73

0

A. Matrix blank

%

100

0.50

1.00

1.50

2.00 min

0

1.04

138

Baseline

x5

B. 1 pg/mL

spiked sample

%

100

0.50

1.00

1.50

2.00 min

%

0

1.04

765

Baseline

x25

C. 5 pg/mL 

spiked sample

100

0.50

1.00

1.50

2.00 min

LC-MS/MS chromatogram of 1 pg/mL of alprazolam from rat plasma.

Selectivity
Having a variety of tools for method 
development allows separation 
scientists to optimize their protocols 
to achieve maximum selectivity 
and sensitivity. Small molecules 
and therapeutic peptides require 
different approaches to sample 
preparation due to their solubilities 
and stabilities. Oasis SPE Products 
are available in a variety of sorbents 
and can be used in conjunction with 
a simple, logical approach to quickly 
develop new separation methods.

* When using the µElution plate, perform the second elution using 5% NH4OH in 60:40 

CH3CN:CH3OH (for protocol 1) and 2% HCOOH in 60:40 CH3CN:CH3OH (for protocol 2).

Oasis 2 X 4 Method Development Protocol

Load

Pre-treated sample

Wash 1 

2% Formic acid

Wash 2 or Elute 1 

100% MeOH

Elute 2 

5% NH4OH in MeOH

4-Step Protocol

Load

Pre-treated sample

Wash 

5% NH4OH

Elute 2

2% Formic Acid in MeOH

Elute

100% MeOH

4-Step Protocol

Bases

Strong Acids

Strong Bases

Acids

pKa 2–10

OASIS MCX

Bases

pKa <1.0

OASIS WAX

Strong Acids

pKa >10

OASIS WCX

Strong Bases

pKa 2–8

OASIS MAX

Acids

NEUTRALS

NEUTRALS

12

A. Matrix blank

%

0

100

1.54

1.58

1.62

1.66

1.70

1.74

1.78 min

B. 1 pg/mL 

spiked sample

%

0

100

1.54

1.58

1.62

1.66

1.70

1.74

1.78 min

1.61

1.52

1.55

1.66

1.73

0

A. Matrix blank

%

100

0.50

1.00

1.50

2.00 min

0

1.04

138

Baseline

x5

B. 1 pg/mL

spiked sample

%

100

0.50

1.00

1.50

2.00 min

%

0

1.04

765

Baseline

x25

C. 5 pg/mL 

spiked sample

100

0.50

1.00

1.50

2.00 min

Peptides
The increasing number of peptide based therapeutics brings new challenges 
to the typical bioanalytical laboratory. Sensitive, selective, and robust 
bioanalytical methods, which would ideally meet current regulatory criteria, 
must be developed for these types of compounds, which differ significantly 
from small molecule drugs.

Because of their size and charge state distribution, sensitivity by mass 
spectrometry may be lower for biomolecules than typical small molecules, 
necessitating sample concentration and other means of increasing 
overall method sensitivity. We provide basic starting protocols for sample 
preparation and show how the use of mixed-mode ion-exchange solid-phase 
extraction in µElution format can simplify the process of method development 
for peptide therapeutics and biomarkers.

Oasis µElution Plate technology for peptides enables:

■

Up to 15x concentration without evaporation

■

Concentration is often necessary to reach the limit of detection (LOD) 
with peptides

■

Helps minimize analyte loss

■

Eliminates problems re-solubilizing peptides after dry-down steps

■

Beneficial for thermally unstable peptides

Oasis WCX 

µElution

Oasis MAX 

µElution 

Dilute plasma with  

4% H3PO4

Condition MeOH/ 

Equilibrate H20 

Wash 1: 5% NH4OH 

Wash 2: 20% ACN 

Elute: 1% TFA in  

75/25 ACN/H2O

PROTOCOL

Dilute: H2O

A. Matrix blank

%

0

100

1.54

1.58

1.62

1.66

1.70

1.74

1.78 min

B. 1 pg/mL 

spiked sample

%

0

100

1.54

1.58

1.62

1.66

1.70

1.74

1.78 min

1.61

1.52

1.55

1.66

1.73

0

A. Matrix blank

%

100

0.50

1.00

1.50

2.00 min

0

1.04

138

Baseline

x5

B. 1 pg/mL

spiked sample

%

100

0.50

1.00

1.50

2.00 min

%

0

1.04

765

Baseline

x25

C. 5 pg/mL 

spiked sample

100

0.50

1.00

1.50

2.00 min

A. Matrix blank

%

0

100

1.54

1.58

1.62

1.66

1.70

1.74

1.78 min

B. 1 pg/mL 

spiked sample

%

0

100

1.54

1.58

1.62

1.66

1.70

1.74

1.78 min

1.61

1.52

1.55

1.66

1.73

0

A. Matrix blank

%

100

0.50

1.00

1.50

2.00 min

0

1.04

138

Baseline

x5

B. 1 pg/mL

spiked sample

%

100

0.50

1.00

1.50

2.00 min

%

0

1.04

765

Baseline

x25

C. 5 pg/mL 

spiked sample

100

0.50

1.00

1.50

2.00 min

LOD and LOQ of Desmopressin from Plasma

LC-MS/MS chromatogram of 1 pg/mL and 5 pg/mL of desmopressin from human plasma.

13

[ OASIS SOLID-PHASE EXTRACTION PRODUCTS ]

Formats

¡

  Ultra-clean syringe barrel and frits.

¡

  Available with cartridges ranging from 1 cc to 60 cc.

¡

  Flangeless syringe-barrel cartridges available in 1 cc, 3 cc, and 6 cc configurations.

¡

  Plus-style cartridges with Luer inlet hub and outlet tip with 225 mg of sorbent.

Sy

rin

ge

-B

ar

re

l 

C

ar

tr

idge

s

¡

  Ultra-clean glass syringe with Teflon® frit.

¡

  For trace level detection and analysis at part-per-trillion levels. 

¡

  Available in 5 cc with 200 mg of sorbent configuration.

G

las

s 

C

ar

tr

idge

s

¡

  For rugged, reproducible, and ultra-fast on-line analysis. 

¡

  Wide choice of configurations, particle sizes, and sorbent chemistries.

¡

  Available with six patented Oasis Sorbents—HLB, PRiME HLB, MCX, MAX, WCX, and WAX. 

¡

  High recovery and reproducible results for a wide range of compounds.

¡

  Cartridge format for use with Spark Holland Prospekt-2™/Symbiosis™  

systems also available. 

O

n-

Li

ne C

ol

um

ns  

an

d C

ar

tr

idge

s

¡

  Innovative, award-winning two-stage well design.

¡

  High throughput and high recovery.

¡

  Available with 5 mg, 10 mg, 30 mg, and 60 mg of sorbent per well. 

¡

  Compatible with most liquid-handling robotic systems for automated, reliable  

high throughput SPE (HT-SPE).

96

-we

l 

Ex

tr

ac

tion

 P

la

te

s

¡

 Patented μElution plate design. 

¡

  Ideal for SPE cleanup and analyte enrichment of sample volumes ranging from 10 µL to 375 µL.

¡

  No evaporation and reconstitution necessary due to elution volumes as low as 25 µL.

¡

  Up to a 15x increase in concentration.

¡

  Compatible with most liquid-handling robotic systems for automated, reliable high  

throughput SPE (HT-SPE).

µE

lut

ion

Pl

at

es

Quality
Waters expert manufacturing capabilities and stringent quality controls have established the highest standard in 
batch-to-batch and lot-to-lot reproducibility for SPE sorbents, enabling scientists to develop robust, accurate, and 
precise analytical methods. Scientists can be confident that the methods can be seamlessly transferred to laboratories 
across the globe.

\HDUV

Reco

ve

ry

 %

No Batch Reservations Needed: Consistently high recoveries over more than 15 years of production.

RSDs of recovery for:

Procainamide: 1.90%

Ranitidine: 1.68%

Acetaminophen: 1.65%

14

Oasis HLB Solid-Phase Extraction Products
Description

Format

Particle Size

Qty.

Part No.

Oasis HLB Cartridge 

1 cc/10 mg

30 µm

100/box

186000383

Oasis HLB Cartridge

1 cc/30 mg

30 µm

100/box

WAT094225

Oasis HLB Cartridge

1 cc/30 mg

30 µm

1,000/box 186003908

Oasis HLB Flangeless Cartridge

1 cc/30 mg

30 µm

100/box

186001879

Oasis HLB Cartridge with Gilson 

ASPEC adapter

1 cc/10 mg

30 µm

500/box

186000988

Oasis HLB Cartridge with Gilson 

ASPEC adapter

1 cc/30 mg

30 µm

500/box

WAT058882

Oasis HLB Cartridge

3 cc/60 mg

30 µm

100/box

WAT094226

Oasis HLB Cartridge

3 cc/60 mg

30 µm

1,000/box

186007646

Oasis HLB Flangeless Cartridge

3 cc/60 mg

30 µm

100/box

186001880

Oasis HLB Cartridge with Gilson 

ASPEC adapter

3 cc/60 mg

30 µm

500/box

WAT058883

Oasis HLB Cartridge

6 cc/200 mg

30 µm

30/box

WAT106202

Oasis HLB Cartridge

3 cc/400 mg

60 µm

100/box

186003849

Oasis HLB Cartridge

3 cc/540 mg

60 µm

100/box

186004134

Oasis HLB Flangeless Cartridge

3 cc/540 mg

60 µm

100/box

186003852

Oasis HLB Cartridge

6 cc/150 mg

30 µm

30/box

186003365

Oasis HLB Cartridge

6 cc/150 mg

60 µm

30/box

186003379

Oasis HLB Cartridge

6 cc/500 mg 

60 µm

30/box

186000115

Oasis HLB Cartridge

12 cc/500 mg

60 µm

20/box

186000116

Oasis HLB Cartridge

20 cc/1 g 

60 µm

20/box

186000117

Oasis HLB Cartridge

35 cc/6 g

60 µm

10/box

186000118

Oasis HLB Plus Short Cartridge

225 mg 

60 µm

50/box

186000132

Oasis HLB Plus Light Cartridge

30 mg

30 µm

50/box

186005125

Oasis HLB Vac RC Cartridge

20 cc/30 mg

30 µm

50/box

186000382

Oasis HLB Vac RC Cartridge

20 cc/60 mg

30 µm

50/box

186000381

Oasis HLB Glass Cartridge

5 cc/200 mg

60 µm

30/box

186000683

Oasis HLB µElution Plate

2 mg/96-well

30 µm

1/pk

186001828BA

Oasis HLB Plate

5 mg/96-well

30 µm

1/pk

186000309

Oasis HLB Plate

10 mg/96-well

30 µm

1/pk

186000128

Oasis HLB Plate

30 mg/96-well

30 µm

1/pk

WAT058951

Oasis HLB Plate

60 mg/96-well

60 µm

1/pk

186000679

Oasis MCX Solid-Phase Extraction Products (Cation Exchange)
Description

Format

Particle Size

Qty.

Part No.

Oasis MCX Cartridge

1 cc/10 mg 

30 µm

100/box

186004648

Oasis MCX Cartridge 

1 cc/30 mg

30 µm

100/box

186000252

Oasis MCX Flangeless Cartridge

1 cc/30 mg

30 µm

100/box

186001881

Oasis MCX Cartridge

1 cc/30 mg

60 µm

100/box

186000782

Oasis MCX Cartridge

3 cc/60 mg

30 µm

100/box

186000254

Oasis MCX Flangeless Cartridge

3 cc/60 mg

30 µm

100/box

186001882

Oasis MCX Cartridge

3 cc/60 mg

60 µm

100/box

186000253

Oasis MCX Cartridge

6 cc/150 mg 

30 µm

30/box

186000256

Oasis MCX Cartridge

6 cc/150 mg

60 µm

30/box

186000255

Oasis MCX Cartridge

6 cc/500 mg

60 µm

30/box

186000776

Oasis MCX Cartridge

20 cc/1 g

60 µm

20/box

186000777

Oasis MCX Cartridge

35 cc/6 g

60 µm

10/box

186000778

Oasis MCX Plus Short Cartridge

225 mg 

60 µm

50/box

186003516

Oasis MCX Vac RC Cartridge

20 cc/60 mg

30 µm

50/box

186000261

Oasis MCX Vac RC Cartridge

20 cc/60 mg

60 µm

50/box

186000380

Oasis MCX µElution Plate

2 mg/96-well

30 µm

1/pk

186001830BA

Oasis MCX Plate

10 mg/96-well

30 µm

1/pk

186000259

Oasis MCX Plate

30 mg/96-well

30 µm

1/pk

186000248

Oasis MCX Plate 

30 mg/96-well

60 µm

1/pk

186000250

Oasis MCX Plate

60 mg/96-well

60 µm

1/pk

186000678

Oasis MAX Solid-Phase Extraction Products (Anion Exchange)
Description

Format

Particle Size

Qty.

Part No.

Oasis MAX Cartridge 

1 cc/10 mg

30 µm

100/box

186004649

Oasis MAX Cartridge 

1 cc/30 mg

30 µm

100/box

186000366

Oasis MAX Flangeless Cartridge 1 cc/30 mg

30 µm

100/box

186001883

Oasis MAX Cartridge 

3 cc/60 mg

30 µm

100/box

186000367

Oasis MAX Cartridge 

3 cc/60 mg

60 µm

100/box

186000368

Oasis MAX Flangeless Cartridge

3 cc/60 mg

30 µm

100/box

186001884

Oasis MAX Cartridge 

6 cc/150 mg 

30 µm

30/box

186000369

Oasis MAX Cartridge 

6 cc/150 mg

60 µm

30/box

186000370

Oasis MAX Cartridge

6 cc/500 mg

60 µm

30/box

186000865

Oasis MAX Plus Short Cartridge

225 mg 

60 µm

50/box

186003517

Oasis MAX Vac RC Cartridge

20 cc/30 mg

30 µm

50/box

186000372

Oasis MAX Vac RC Cartridge

20 cc/60 mg

30 µm

50/box

186000371

Oasis MAX Vac RC Cartridge

20 cc/60 mg

60 µm

50/box

186000378

Oasis WCX Solid-Phase Extraction Products (Weak Cation Exchange)
Description

Format

Particle Size

Qty.

Part No.

Oasis WCX Cartridge

1 cc/10 mg

30 µm

100/box

186004650

Oasis WCX Cartridge

1 cc/30 mg

30 µm

100/box  186002494

Oasis WCX Cartridge 

3 cc/60 mg

30 µm

100/box

186002495

Oasis WCX Cartridge 

6 cc/150 mg

30 µm

30/box

186002498

Oasis WCX Cartridge 

1 cc/30 mg

60 µm

100/box

186002496

Oasis WCX Cartridge 

3 cc/60 mg

60 µm

100/box

186002497

Oasis WCX Cartridge

6 cc/500 mg

60 µm

30/box

186004646

Oasis WCX Plus Short Cartridge

225 mg

60 µm

50/box

186003518

Oasis WCX µElution Plate

2 mg/96-well

30 µm

1/pk

186002499

Oasis WCX 96-well Plate 

10 mg/96-well

30 µm

1/pk

186002501

Oasis WCX 96-well Plate 

30 mg/96-well

30 µm

1/pk

186002503

Oasis WAX Solid-Phase Extraction Products (Weak Anion Exchange)
Description

Format

Particle Size

Qty.

Part No.

Oasis WAX Cartridge

1 cc/10 mg

30 µm

100/box

186004651

Oasis WAX Cartridge 

1 cc/30 mg

30 µm

100/box  186002489

Oasis WAX Cartridge 

3 cc/60 mg

30 µm

100/box

186002490

Oasis WAX Cartridge 

6 cc/150 mg

30 µm

30/box

186002493

Oasis WAX Cartridge 

1 cc/30 mg

60 µm

100/box

186002491

Oasis WAX Cartridge 

3 cc/60 mg

60 µm

100/box

186002492

Oasis WAX Cartridge

6 cc/500 mg

60 µm

30/box

186004647

Oasis WAX Plus Cartridge

225 mg 

60 µm

50/box

186003519

Oasis WAX µElution Plate

2 mg/96-well

30 µm

1/pk

186002500

Oasis WAX 96-well Plate 

10 mg/96-well

30 µm

1/pk

186002502

Oasis WAX 96-well Plate 

30 mg/96-well

30 µm

1/pk

186002504

Oasis WAX 96-well Plate

60 mg

30 µm

1/pk

186003915

Oasis PRiME HLB Solid-Phase Extraction Products
Description

Format

Qty.

Part No.

Oasis PRiME HLB µElution Plate

3 mg

1/pk

186008052

Oasis PRiME HLB 96-well Plate

10 mg

1/pk

186008053  

Oasis PRiME HLB 96-well Plate

30 mg

1/pk

186008054  

Oasis PRiME HLB Cartridge

1 cc/30 mg

100/box

186008055  

Oasis PRiME HLB Cartridge

3 cc/60 mg

100/box

186008056  

Oasis PRiME HLB Cartridge

3 cc/150 mg

100/box

186008717

Oasis PRiME HLB Cartridge

6 cc/200 mg

30/box

186008057

Oasis PRiME HLB Cartridge

6 cc/500 mg

30/box

186008718

Oasis PRiME HLB Plus Light Cartridge

Plus Light/100 mg

50/box

186008886

Oasis PRiME HLB Plus Short Cartridge

Plus Light/335 mg

50/box

186008887

Oasis MAX Solid-Phase Extraction Products (Anion Exchange) Continued
Description

Format

Particle Size

Qty.

Part No.

Oasis MAX µElution Plate

2 mg/96-well

30 µm

1/pk

186001829

Oasis MAX Plate

10 mg/96-well

30 µm

1/pk

186000375

Oasis MAX Plate

30 mg/96-well

30 µm

1/pk

186000373

Oasis MAX Plate

60 mg/96-well

30 µm

1/pk

186001256

Oasis MAX Plate

60 mg/96-well

60 µm

1/pk

186001205

15

[ OASIS SOLID-PHASE EXTRACTION PRODUCTS ]

Therapeutic Peptide Method Development Kits
Description

Part No.

UPLC® Therapeutic Peptide Method Development Kit Includes:
1 Oasis Peptide Method Development 96-well µElution Plate,  

(part no.: 186004713)
1 ACQUITY UPLC® Peptide BEH C18, 300Å, 1.7 µm, 2.1 x 50 mm Column, (part 

no.: 186003685)
3 96-well 1 mL Collection Plate and Cap Mat, (part no.: 600001043)

176001835

HPLC Therapeutic Peptide Method Development Kit Includes:
1 Oasis Peptide Method Development 96-well µElution Plate,  

(part no.: 186004713)
1 XBridge® Peptide BEH C18, 300Å, 3.5 µm, 2.1 x 50 mm Column,  

(part no.: 186003607)
3 96-well 1 mL Collection Plate and Cap Mat, (part no.: 600001043)

176001836

Oasis Method Development Kits
Description

Format

Particle Size Part No.

Oasis Sorbent Selection Plate, 3 rows each: 

MCX, MAX, WCX, and WAX

10 mg/96-well

30 µm

186003249

Oasis µElution Sorbent Selection Plate,  

3 rows each: MCX, MAX, WCX, and WAX

2 mg/96-well

30 µm

186004475

Oasis Sorbent Selection Cartridge Kit,  

10 each: MCX, MAX, WCX, and WAX

1 cc/30 mg

30 µm

186003463

Oasis Sorbent Selection Flangeless Cartridge 

Kit, 10 each: MCX, MAX, WCX, and WAX

1 cc/10 mg

30 µm

186006344

Oasis Sorbent Selection Flangeless Cartridge 

Kit, 10 each: MCX, MAX, WCX, and WAX

1 cc/30 mg

30 µm

186006345

Oasis µElution 96-well Plates
Description

Particle Size

Qty.

Part No.

Oasis PRiME HLB

—

1/pk

186008052

Oasis HLB

30 µm

1/pk

186001828BA

Oasis MCX

30 µm

1/pk

186001830BA

Oasis MAX

30 µm

1/pk

186001829

Oasis WCX

30 µm

1/pk

186002499

Oasis WAX

30 µm

1/pk

186002500

Oasis 96-well Plates

Particle 

Size

5 mg/ 

96-well

10 mg/ 

96-well

30 mg/ 

96-well

60 mg/ 

96-well

Description

1/pk

1/pk

1/pk

1/pk

Oasis PRiME HLB

—

—

186008053

186008054

—

Oasis HLB

30 µm

186000309

186000128

WAT058951

—

Oasis HLB

60 µm

—

—

—

186000679

Oasis MCX

30 µm

—

186000259

186000248

—

Oasis MCX

60 µm

—

—

186000250

186000678

Oasis MAX

30 µm

—

186000375

186000373

186001256

Oasis MAX

60 µm

—

—

—

186001205

Oasis WCX

30 µm

—

186002501

186002503

—

Oasis WAX

30 µm

—

186002502

186002504

186003915

Oasis Symbiosis/Prospekt-2 Cartridges
Description

Format

Particle 

Size

Qty.

Part No.

Oasis HLB Symbiosis/Prospekt-2 Cartridge

1 x 10 mm

30 µm 96/box 186005781

Oasis HLB Symbiosis/Prospekt-2 Cartridge

1 x 20 mm

30 µm 96/box 186005786

Oasis MCX Symbiosis/Prospekt-2 Cartridge

1 x 10 mm

30 µm 96/box 186005782

Oasis MCX Symbiosis/Prospekt-2 Cartridge 1 x 20 mm

30 µm 96/box 186004653

Oasis MAX Symbiosis/Prospekt-2 Cartridge

1 x 10 mm

30 µm 96/box 186005783

Oasis MAX Symbiosis/Prospekt-2 Cartridge 1 x 20 mm

30 µm 96/box 186004654

Oasis WCX Symbiosis/Prospekt-2 Cartridge 1 x 10 mm

30 µm 96/box 186005784

Oasis WCX Symbiosis/Prospekt-2 Cartridge 1 x 20 mm

30 µm 96/box 186004655

Oasis WAX Symbiosis/Prospekt-2 Cartridge

1 x 10 mm

30 µm 96/box 186005785

Oasis WAX Symbiosis/Prospekt-2 Cartridge 1 x 20 mm

30 µm 96/box 186004656

SPE Columns for Waters UPLC with On-Line SPE Technology
Description

Format

Particle 

Size

Qty.

Part No.

Oasis HLB Direct Connect HP Column

2.1 x 30 mm

20 µm

1/pk

186005231

XBridge C18 Direct Connect HP Column

2.1 x 30 mm

10 µm

1/pk 186005232

XBridge C8 Direct Connect HP Column

2.1 x 30 mm

10 µm

1/pk 186005233

Oasis Bulk Material and Glass Cartridge
Description

Particle Size

Qty.

Part No.

Oasis HLB

30 µm/100 gm

—

186007549

Oasis HLB

30 µm/250 gm

—

186007550

Oasis MAX

30 µm/100 gm

—

186007551

Oasis MAX

30 µm/250 gm

—

186007552

Oasis MCX

30 µm/100 gm

—

186007553

Oasis MCX

30 µm/250 gm

—

186007554

Oasis HLB Glass Cartridge

60 µm

30/box 

186000683

On-Line SPE Columns and Cartridge Columns
Description

Format

Particle Size

Qty.

Part No.

Oasis HLB Column

2.1 x 20 mm

5 µm

1/pk

186002034

Oasis HLB Column

3.0 x 20 mm

5 µm

1/pk

186002037

Oasis HLB Column

3.9 x 20 mm

5 µm

1/pk

186002040

Oasis HLB Cartridge Column

3.9 x 20 mm 

5 µm

1/pk

186001413

Oasis HLB Column

4.6 x 20 mm

5 µm

1/pk

186002043

Oasis HLB Column

2.1 x 20 mm

15 µm

1/pk

186002035

Oasis HLB Column

3.0 x 20 mm

15 µm

1/pk

186002038

Oasis HLB Column

3.9 x 20 mm

15 µm

1/pk

186002041

On-Line SPE Columns and Cartridge Columns Continued
Description

Format

Particle Size

Qty.

Part No.

Oasis HLB Cartridge Column

3.9 x 20 mm

15 µm

1/pk

186001414

Oasis HLB Column

4.6 x 20 mm

15 µm

1/pk

186002044

Oasis HLB Column

2.1 x 20 mm

25 µm

1/pk

186002036

Oasis HLB Cartridge Column

2.1 x 20 mm 

25 µm

1/pk

186000706

Oasis HLB Column

3.0 x 20 mm

25 µm

1/pk

186002039

Oasis HLB Column

3.9 x 20 mm

25 µm

1/pk

186002042

Oasis HLB Column

4.6 x 20 mm

25 µm

1/pk

186002045

Oasis HLB Direct Connect Column 

2.0 x 15 mm 

25 µm

1/pk

186001792

Oasis MCX Column

2.1 x 20 mm

30 µm

1/pk

186002046

Oasis MCX Cartridge Column

2.1 x 20 mm

30 µm

1/pk

186002051

Oasis MCX Column

3.0 x 20 mm

30 µm

1/pk

186002047

Oasis MCX Column

3.9 x 20 mm

30 µm

1/pk

186002048

Oasis MCX Column

4.6 x 20 mm

30 µm

1/pk

186002049

Oasis MAX Column

2.1 x 20 mm

30 µm

1/pk

186002052

Oasis MAX Cartridge Column

2.1 x 20 mm

30 µm

1/pk

186002057

Oasis MAX Column

3.0 x 20 mm

30 µm

1/pk

186002053

Oasis MAX Column

3.9 x 20 mm

30 µm

1/pk

186002054

Oasis MAX Column

4.6 x 20 mm

30 µm

1/pk

186002055

Oasis WCX Column

2.1 x 20 mm

30 µm

1/pk

186002505

Oasis WCX Column 

3.9 x 20 mm

30 µm

1/pk

186002507

Oasis WAX Column 

2.1 x 20 mm

30 µm 

1/pk

186002508

Oasis WAX Column 

3.9 x 20 mm

30 µm

1/pk

186002509

Waters Corporation 
34 Maple Street 
Milford, MA 01757 U.S.A. 
T: 1 508 478 2000 
F: 1 508 872 1990 
www.waters.com

www.waters.com/oasis

Waters, The Science of What’s Possible, UPLC, ACQUITY UPLC, XBridge, and Oasis are registered 
trademarks of Waters Corporation. Teflon is a registered trademark of E.I. du Pont de Nemours 
and Company or its affiliates. Prospekt and Symbiosis are trademarks of Spark Holland. All other 
trademarks are the property of their respective owners.

©2017 Waters Corporation. Printed in the U.S.A.
April 2020  720001692EN  KP-SIG

For your local sales  

office, please visit  

waters.com/contact